https://consulting.drcarlad.com/ daily 1.0 https://consulting.drcarlad.com/blog daily 0.8 https://consulting.drcarlad.com/blog/women-s-hormonal-health-and-athletic-performance-a-physician-scientist-s-guide weekly 0.6 https://consulting.drcarlad.com/blog/estrogen-s-role-in-muscle-mass-bone-density-and-injury-risk-in-female-athletes weekly 0.6 https://consulting.drcarlad.com/blog/what-femtech-companies-get-wrong-about-female-athletic-performance weekly 0.6 https://consulting.drcarlad.com/blog/red-s-in-female-athletes-what-companies-developing-women-s-nutrition-products-need-to-know weekly 0.6 https://consulting.drcarlad.com/blog/testosterone-in-women-what-it-does-what-it-doesn-t-and-why-the-science-is-often-misrepresented weekly 0.6 https://consulting.drcarlad.com/blog/how-crossfit-training-affects-women-s-hormones-a-physician-scientist-perspective weekly 0.6 https://consulting.drcarlad.com/blog/hiring-a-women-s-health-medical-advisor-for-a-sports-or-fitness-brand-what-to-look-for weekly 0.6 https://consulting.drcarlad.com/blog/what-fertility-companies-and-startups-need-in-a-medical-advisor-a-complete-guide weekly 0.6 https://consulting.drcarlad.com/blog/ovarian-reserve-and-egg-quality-what-the-science-actually-says weekly 0.6 https://consulting.drcarlad.com/blog/amh-testing-what-direct-to-consumer-fertility-companies-must-get-medically-right weekly 0.6 https://consulting.drcarlad.com/blog/how-reproductive-endocrinologists-can-help-fertility-startups-avoid-scientific-and-regulatory-risk weekly 0.6 https://consulting.drcarlad.com/blog/egg-freezing-technology-and-patient-communication-where-companies-make-medical-accuracy-mistakes weekly 0.6 https://consulting.drcarlad.com/blog/fertility-supplements-what-ingredients-have-evidence-and-which-are-marketing weekly 0.6 https://consulting.drcarlad.com/blog/pcos-in-product-development-what-companies-building-for-this-population-should-understand weekly 0.6 https://consulting.drcarlad.com/blog/male-factor-infertility-what-fertility-companies-and-platforms-should-communicate-accurately weekly 0.6 https://consulting.drcarlad.com/blog/menopause-science-for-companies-what-every-menopause-health-startup-needs-to-get-right weekly 0.6 https://consulting.drcarlad.com/blog/hrt-misinformation-what-menopause-companies-and-content-creators-often-get-wrong weekly 0.6 https://consulting.drcarlad.com/blog/perimenopause-symptoms-and-the-hormone-changes-behind-them-a-scientific-primer-for-founders weekly 0.6 https://consulting.drcarlad.com/blog/menopause-supplements-what-has-evidence-what-doesn-t-and-how-to-review-claims-accurately weekly 0.6 https://consulting.drcarlad.com/blog/genitourinary-syndrome-of-menopause-what-digital-health-platforms-often-miss weekly 0.6 https://consulting.drcarlad.com/blog/what-is-a-menopause-society-certified-practitioner-and-why-it-matters-for-advisory-credibility weekly 0.6 https://consulting.drcarlad.com/blog/brain-fog-mood-and-cognition-in-menopause-what-companies-developing-solutions-should-know weekly 0.6 https://consulting.drcarlad.com/blog/menopause-and-athletic-performance-the-science-of-exercise-through-the-menopausal-transition weekly 0.6 https://consulting.drcarlad.com/blog/translational-medicine-in-reproductive-health-bridging-bench-science-and-clinical-reality weekly 0.6 https://consulting.drcarlad.com/blog/stem-cell-research-in-reproductive-medicine-where-the-science-is-and-where-it-isn-t weekly 0.6 https://consulting.drcarlad.com/blog/mesenchymal-stem-cells-and-endometrial-repair-a-scientist-s-review-of-the-current-evidence weekly 0.6 https://consulting.drcarlad.com/blog/ovarian-aging-biology-what-investors-and-founders-in-longevity-and-fertility-tech-should-understand weekly 0.6 https://consulting.drcarlad.com/blog/what-is-scientific-due-diligence-and-why-reproductive-biotech-companies-need-it weekly 0.6 https://consulting.drcarlad.com/blog/embryo-implantation-biology-a-primer-for-companies-building-in-ivf-and-reproductive-technology weekly 0.6 https://consulting.drcarlad.com/blog/how-to-evaluate-preclinical-study-data-when-advising-on-reproductive-health-products weekly 0.6 https://consulting.drcarlad.com/blog/scientific-claim-review-for-women-s-health-companies-what-it-is-why-it-matters-and-how-it-works weekly 0.6 https://consulting.drcarlad.com/blog/ftc-health-claim-rules-what-every-women-s-wellness-brand-needs-to-know weekly 0.6 https://consulting.drcarlad.com/blog/5-common-scientific-mistakes-women-s-health-supplement-brands-make weekly 0.6 https://consulting.drcarlad.com/blog/how-to-audit-your-health-platform-s-medical-content-for-scientific-accuracy weekly 0.6 https://consulting.drcarlad.com/blog/the-difference-between-peer-reviewed-evidence-and-marketing-science-a-guide-for-health-brands weekly 0.6 https://consulting.drcarlad.com/blog/what-investors-ask-about-scientific-credibility-in-women-s-health-startups weekly 0.6 https://consulting.drcarlad.com/blog/when-your-app-or-platform-needs-a-medical-reviewer-vs-a-medical-director weekly 0.6 https://consulting.drcarlad.com/blog/hormone-testing-kits-and-dtc-labs-what-companies-need-to-communicate-accurately weekly 0.6 https://consulting.drcarlad.com/blog/how-to-find-and-hire-a-femtech-medical-advisor-a-founder-s-guide weekly 0.6 https://consulting.drcarlad.com/blog/what-does-a-medical-advisor-actually-do-roles-deliverables-and-scope-explained weekly 0.6 https://consulting.drcarlad.com/blog/the-state-of-femtech-in-2025-market-trends-every-founder-should-know weekly 0.6 https://consulting.drcarlad.com/blog/women-s-health-venture-capital-what-scientific-credibility-means-to-investors weekly 0.6 https://consulting.drcarlad.com/blog/advisory-board-vs-medical-director-vs-consultant-which-does-your-health-company-need- weekly 0.6 https://consulting.drcarlad.com/blog/what-a-physician-scientist-consultant-costs-engagement-models-explained weekly 0.6 https://consulting.drcarlad.com/blog/regulatory-landscape-for-women-s-health-products-what-brands-building-in-this-space-must-navigate weekly 0.6 https://consulting.drcarlad.com/blog/why-women-s-health-has-been-underfunded-and-what-that-means-for-founders-now weekly 0.6